10-Q: Aligos Therapeutics Q2 2025: Pipeline Progress & Funding

Aligos Therapeutics reported a net income for Q2 2025 driven by a non-cash warrant re-measurement gain, while advancing its clinical pipeline for HBV, MASH, and coronavirus with new trial initiations and positive Phase 2a data for MASH.

Summary

• Reported a net income of $27.2 million for the six months ended June 30, 2025, primarily due to a non-cash gain of $63.2 million from the change in fair value of 2023 common warrants.
• Incurred a net loss of $15.9 million for the three months ended June 30, 2025.
• Cash, cash equivalents, and investments totaled $122.9 million as of June 30, 2025, expected to fund operations for at least 12 months.
• Operating expenses decreased by 23% to $39.1 million for the six months ended June 30, 2025, driven by a 24% reduction in R&D expenses and a 19% reduction in G&A expenses.
• Revenue from customers decreased by 27% to $1.3 million for the six months ended June 30, 2025, due to the near completion of the original Amoytop agreement.
• The chronic Hepatitis B virus (HBV) infection program (ALG000184) is advancing, with Phase 2 B-SUPREME study site activation and screening initiated, and dosing expected to commence in the coming weeks.
• Positive topline data from the Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) drug candidate ALG055009 was announced in 2024, showing statistically significant reductions in liver fat.
• The pan-coronavirus program (ALG097558) has completed Phase 1 and initiated three additional clinical trials in 2024, with approximately $15.3 million in NIH/NIAID funding expected.
• Stockholders approved an amendment on June 25, 2025, to increase authorized shares of voting and non-voting common stock.

Sentiment

Score: 5

Explanation: The company is a high-risk, clinical-stage biotech with no product revenue and ongoing operational losses. However, it has a solid cash runway for the next 12 months due to a recent significant capital raise. Positive Phase 2a data for MASH and advancement of HBV and coronavirus programs provide some positive momentum, but the long and uncertain path to commercialization and continued need for substantial funding temper the outlook.

Positives

• Achieved a net income of $27.2 million for the six months ended June 30, 2025, largely due to a significant non-cash gain from warrant re-measurement.
• Maintained a strong cash position of $122.9 million as of June 30, 2025, providing at least 12 months of operational funding.
• Successfully completed a PIPE offering in February 2025, raising $101.4 million in net proceeds, bolstering capital resources.
• Reduced total operating expenses by 23% for the six months ended June 30, 2025, demonstrating cost management.
• The MASH program (ALG055009) reported positive topline data from its Phase 2a HERALD study in 2024, meeting the primary endpoint with statistically significant liver fat reductions.
• Received affirmative feedback from the FDA, CHMP (EU), and NMPA (China) supporting the chronic suppressive therapy pathway for ALG000184 in HBV.
• The pan-coronavirus program (ALG097558) is supported by approximately $15.3 million in federal funds from NIH/NIAID contracts.
• Phase 1 data for ALG000184 (HBV) demonstrated potentially best-in-class multi-log10 HBV DNA and RNA reductions, and HBsAg reductions in a subset of subjects, suggesting potential superiority to current standard of care NAs.

Negatives

• Incurred a net loss of $15.9 million for the three months ended June 30, 2025, indicating ongoing operational losses despite the six-month net income driven by a non-cash gain.
• Revenue from customers decreased by 27% for the six months ended June 30, 2025, compared to the same period in 2024.
• No revenue was recognized from collaborations for the three and six months ended June 30, 2025, due to the termination of the Merck collaboration agreement.
• The company has incurred significant losses since inception and expects to continue incurring substantial losses for the foreseeable future, with no product revenue generated to date.
• Discontinued further development of ALG-010133 due to insufficient antiviral activity and ALG-020572 due to an unanticipated serious adverse event (ALT flares).
• Further clinical evaluation of ALG-125755 (siRNA) is not prioritized with current funding and requires additional external funding.
• The company will require substantial additional financing to achieve its goals, which may not be available on acceptable terms or at all, posing a significant risk to product development and commercialization efforts.

Risks

• The company is a clinical-stage biotechnology company with a limited operating history and no products approved for commercial sale, having incurred significant losses since inception and expecting to incur losses for at least the next several years.
• Substantial additional financing will be required to achieve goals, and failure to obtain necessary capital could force delays, limits, reductions, or termination of product development or commercialization efforts.
• Business is dependent on the successful development of current and future drug candidates; inability to advance them through clinical trials, obtain marketing approval, or commercialize them, or significant delays, would materially harm the business.
• Current or future drug candidates may cause undesirable side effects or have other properties that could delay or halt clinical development, prevent marketing approval, limit commercial potential, or result in significant negative consequences.
• Dependence on collaborations with third parties for the development of certain potential drug candidates, and potential future dependence on additional collaborations for development and commercialization, carries risks of unsuccessful outcomes.
• Intention to develop current and future drug candidates in combination with other therapies exposes the company to additional risks.
• Significant competition exists, and if competitors develop and market more effective, safer, or less expensive products, commercial opportunities will be negatively impacted.
• Inability to obtain, maintain, protect, and enforce sufficient patent and other intellectual property protection for drug candidates and technology could allow competitors to develop and commercialize similar products.
• Third parties may initiate legal proceedings alleging intellectual property infringement, misappropriation, or violation, with uncertain outcomes that could negatively impact business success.
• Failure to comply with obligations in licensing and collaboration agreements, or termination of these agreements, or disruptions to business relationships with licensors or licensees, could harm competitive position and financial condition.
• High dependence on key personnel, and inability to attract, motivate, and retain highly qualified personnel, may hinder successful implementation of business strategy.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing results to fall below expectations.
• Business could be materially adversely affected by health pandemics or epidemics, particularly in regions with significant manufacturing facilities, clinical trial sites, or business operations.
• Nonclinical development is uncertain, and programs may experience delays or never advance to clinical trials.
• Regulatory approval processes are lengthy, time-consuming, complex, and inherently unpredictable, potentially preventing or substantially harming the business if approvals are not obtained.
• Interim, topline, and preliminary data from clinical trials may differ materially from final data, impacting program value and approvability.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Changes in methods of drug candidate manufacturing or formulation may result in additional costs or delays.
• Even if marketing approval is received, products may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Adverse events in therapeutic areas of focus could damage public perception and negatively affect the business.
• Ongoing regulatory obligations and continued regulatory review, even after marketing approval, may result in significant additional expense and penalties for non-compliance.
• Failure to obtain approval outside the United States would limit market opportunities.
• Risks associated with international trade policies or international operations, including seeking and obtaining foreign approvals, could harm the business.
• Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to review and approve products.
• Market opportunities for drug candidates may be smaller than believed, or approvals may be based on narrower patient populations.
• The One Big Beautiful Bill Act (OBBBA) enacted in July 2025 imposes significant reductions in Medicaid funding, which could adversely affect sales of commercialized products.
• Actual or perceived failure to comply with current or future data privacy and protection laws could lead to investigations, penalties, and adverse publicity.
• Information technology systems, or those of CROs/contractors, failing or suffering security breaches could disrupt operations and expose the company to harm.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of approved products.
• Current and future healthcare reform legislation or regulation may increase the difficulty and cost of commercializing products and affect prices.
• The price of common stock may be volatile and fluctuate substantially, resulting in losses for investors.
• The dual class structure of common stock may limit the ability to influence corporate matters and visibility with respect to certain transactions.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes.
• If securities analysts do not publish research or publish negative evaluations, the stock price could decline.
• Failure to implement and maintain proper and effective internal control over financial reporting could impair accurate and timely financial statements.
• Provisions in charter documents and Delaware law could discourage a takeover and lead to entrenchment of management.
• Claims for indemnification by directors and officers may reduce available funds.
• Exclusive forum provision in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Unfavorable global economic conditions could adversely affect business, financial condition, stock price, and results of operations.
• Insurance policies are expensive and protect only from some business risks, leaving significant uninsured liabilities.
• Subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, violations of which can have serious negative consequences.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements.
• Intellectual property litigation could cause substantial resource expenditure and distract personnel.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• If trademarks and trade names are not adequately protected, name recognition may not be built.
• Strategic transactions may affect liquidity, dilute stockholders, increase expenses, and present significant management challenges or prove unsuccessful.

Future Outlook

The company expects to fund operations for at least the next 12 months with existing cash. For the HBV program (ALG000184), dosing in the Phase 2 B-SUPREME study is expected to commence in the coming weeks, with interim data projected in 2026 and topline data in 2027. The company is exploring options to fund continued development of the MASH program (ALG055009), including potential out-licensing. For the coronavirus program (ALG097558), the company is seeking additional external funding (e.g., from governmental agencies) to support future studies.

Management Comments

• The company is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections.
• The Aligos team has a demonstrated track record of success in early drug development and medicinal chemistry in liver and viral diseases, resulting in three potential best-in-class drug candidates currently in development.
• ALG000184 (HBV) has superior DMPK properties with enhanced absorption and high liver uptake, with a ~2-300-fold improvement in in vitro potency compared to other known CAMs.
• ALG055009 (MASH) has been purposefully designed to exhibit significantly greater potency (approximately 50-fold higher compared to resmetirom in head-to-head in vitro studies) and enhanced β-selectivity, along with optimized pharmacologic properties to deliver an improved PK profile.
• ALG097558 (coronavirus) has been at least 3-fold more potent in cell-based assays of coronavirus infection than other approved CoV PIs and can be dosed twice daily without the requirement for ritonavir co-dosing based on Phase 1 clinical studies.
• The company expects to finance its cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and/or other marketing or distribution arrangements.

Industry Context

The company operates in the highly competitive life sciences industry, specifically targeting chronic HBV infection, MASH, and coronavirus infections. For HBV, the market is dominated by existing treatments like peg-IFN and nucleoside analogs (e.g., Gilead, Bristol-Myers Squibb), which do not offer functional cures, creating a need for novel therapies. Many companies are developing new mechanisms of action, including oligonucleotide agents (Arbutus, Ionis/GSK, Arrowhead/Janssen, Vir/Alnylam), CAM-Es (Assembly Biosciences, Enanta Pharmaceuticals), and therapeutic vaccines (GSK, Janssen, Dynavax, Johnson & Johnson, Merck). In MASH, the recent FDA approval of resmetirom (Madrigal Pharmaceuticals) marks a significant milestone, but the company believes there's a need for agents with improved efficacy and risk-benefit profiles, with numerous other pharmaceutical and biotechnology companies (AbbVie, AstraZeneca, Eli Lilly, Merck, Pfizer, Novo Nordisk, 89bio, Akero, Gilead, Inventiva, MediciNova, Viking) actively pursuing treatments. For COVID-19, the landscape includes approved oral antivirals like Paxlovid (Pfizer) and molnupiravir (Merck), as well as vaccines, which could reduce the demand for new therapies. The company's strategy involves developing potential best-in-class candidates in these areas, often in collaboration with academic institutions and seeking external funding, particularly for the coronavirus program, reflecting a broader industry trend of diversified funding for high-risk, high-reward drug development.

Comparison to Industry Standards

• ALG000184 (HBV) has demonstrated ~2-300-fold improvement in in vitro potency compared to other known CAMs, and Phase 1 data suggest it may be superior to standard of care nucleos(t)ide analogs (TDF and TAF from Gilead) in achieving HBV DNA levels <LLOQ after 48 weeks.
• ALG055009 (MASH) exhibits approximately 50-fold higher potency compared to resmetirom (Madrigal Pharmaceuticals, Inc.) in head-to-head in vitro studies, positioning it as a strong candidate for a best-in-class THR-β agonist.
• ALG097558 (pan-coronavirus) has been at least 3-fold more potent in cell-based assays of coronavirus infection than nirmatrelvir (Pfizer's Paxlovid component) and other PIs in clinical development, and is designed to be dosed without ritonavir co-dosing, unlike Paxlovid.

Corporate Governance

Legal Proceedings

• Not currently involved in any legal proceedings that are, individually or in the aggregate, material to the business, results of operations, or financial condition.

Stakeholder Impact

• **Shareholders:** Potential for future dilution from additional capital raises (e.g., exercise of warrants, new equity offerings). Stock price volatility is a significant risk due to the early stage of drug development and reliance on clinical trial outcomes. The recent PIPE offering provided capital but also increased outstanding shares.
• **Employees:** Continued investment in R&D and potential growth in the organization may lead to increased hiring, but the company's dependence on key personnel and intense competition for skilled individuals pose retention challenges. Stock-based compensation is a significant component of employee remuneration.
• **Customers/Patients:** Potential for new therapeutic options for chronic HBV, MASH, and coronavirus infections if drug candidates successfully complete development and gain regulatory approval. However, the long development timelines and high failure rates in clinical trials mean no immediate impact.
• **Suppliers/Creditors:** Reliance on third-party manufacturers and CROs for clinical supplies and trial conduct means their performance and stability are critical. The company's financial health and ability to secure future funding directly impact its ability to meet obligations to suppliers.
• **Regulatory Authorities:** The company is actively engaging with regulatory bodies (FDA, CHMP, NMPA) for its drug candidates, indicating compliance efforts and progress towards potential approvals. Regulatory feedback and requirements significantly influence development timelines and costs.

Next Steps

• Commence dosing in the Phase 2 B-SUPREME study for ALG000184 (HBV) in the coming weeks.
• Present 96-week safety, PK, antiviral activity, and certain post-treatment data for ALG000184 (HBV) at upcoming scientific conferences.
• Announce interim data for the HBV Phase 2 B-SUPREME study in 2026.
• Announce topline data for the HBV Phase 2 B-SUPREME study in 2027.
• Evaluate a variety of options to fund continued development of ALG055009 (MASH), including potential out-licensing.
• Continue clinical studies evaluating PK in special populations (renal and hepatic impairment subjects) for ALG097558 (coronavirus) under NIAID contract.
• Continue drug-drug interaction and relative bioavailability study in healthy volunteers for ALG097558 (coronavirus) sponsored by NIAID.
• Seek additional external funding (e.g., from governmental agencies) to support future studies for ALG097558 (coronavirus).

Key Dates

Recommendation

Aligos Therapeutics is a high-risk, clinical-stage biotechnology company with no commercial products and a history of significant operating losses. While the recent PIPE offering has provided a cash runway for at least 12 months and the company has shown promising early-stage clinical data for its MASH and HBV programs, the path to market approval is long, expensive, and uncertain. The reported net income is primarily a non-cash accounting gain, masking continued operational cash burn. Investors should 'hold' due to the inherent high risk of biotech development and the need for further substantial financing, balanced by the potential upside from advancing pipeline assets and positive early clinical results. A 'buy' would be premature given the significant remaining development hurdles and lack of product revenue, while a 'sell' is not warranted given the recent funding and pipeline progress.

Keywords

Biotechnology, Clinical Stage, Drug Development, HBV, MASH, Coronavirus, Liver Diseases, Viral Diseases, SEC Filing, 10-Q, Financial Results, Clinical Trials, Biopharma